Roche Holding AG Stock

Equities

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange 11:30:51 2024-04-16 am EDT 5-day change 1st Jan Change
221.5 CHF -1.60% Intraday chart for Roche Holding AG -0.14% -9.41%
Sales 2024 * 59.76B 65.48B Sales 2025 * 63.39B 69.45B Capitalization 181B 199B
Net income 2024 * 13.29B 14.56B Net income 2025 * 14.67B 16.07B EV / Sales 2024 * 3.26 x
Net Debt 2024 * 13.69B 15B Net Debt 2025 * 7.58B 8.3B EV / Sales 2025 * 2.98 x
P/E ratio 2024 *
13.6 x
P/E ratio 2025 *
12.1 x
Employees 103,605
Yield 2024 *
4.26%
Yield 2025 *
4.43%
Free-Float 88.91%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Roche Holding AG

1 day-1.18%
1 week+0.41%
Current month-3.05%
1 month-3.01%
3 months-10.96%
6 months-11.68%
Current year-8.92%
More quotes
1 week
222.10
Extreme 222.1
228.90
1 month
217.00
Extreme 217
232.00
Current year
217.00
Extreme 217
255.90
1 year
217.00
Extreme 217
293.55
3 years
217.00
Extreme 217
404.20
5 years
217.00
Extreme 217
404.20
10 years
206.35
Extreme 206.35
404.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 02-12-31
Chairman 57 07-12-31
Director of Finance/CFO 57 11-03-31
Members of the board TitleAgeSince
Director/Board Member 72 15-03-02
Director/Board Member 59 -
Director/Board Member 65 95-12-31
More insiders
Date Price Change Volume
24-04-16 221.5 -1.60% 1,195,512
24-04-15 225.1 +0.04% 761,091
24-04-12 225 -0.49% 1,292,148
24-04-11 226.1 +0.76% 1,355,646
24-04-10 224.4 +1.17% 1,052,844

Delayed Quote Swiss Exchange, April 16, 2024 at 07:51 am EDT

More quotes
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
225.1 CHF
Average target price
281.6 CHF
Spread / Average Target
+25.10%
Consensus